
Corporate GovernanceJun 25, 2026, 08:36 AM
SELLAS Life Sciences Amends Executive Compensation Agreements
AI Summary
SELLAS Life Sciences Group, Inc. has amended compensatory arrangements for its President and CEO, Dr. Angelos Stergiou, and entered into amended severance and change of control agreements with CFO John Burns and Chief Development Officer Dr. Dragan Cicic. Dr. Stergiou's amendment provides for lump-sum payments for change-of-control severance benefits. The new agreements for Mr. Burns and Dr. Cicic detail severance terms for both non-change of control and change of control scenarios, including salary, bonus, COBRA benefits, and equity vesting.
Key Highlights
- CEO Dr. Angelos Stergiou's change-of-control severance benefits will now be paid as a lump sum.
- CFO John Burns and CDO Dr. Dragan Cicic's non-change of control severance includes 9 months base salary, pro-rata target bonus, and 9 months COBRA.
- CFO John Burns and CDO Dr. Dragan Cicic's change of control severance includes a lump sum equal to 15 months of base salary.
- CFO John Burns and CDO Dr. Dragan Cicic's change of control severance includes a lump sum equal to their target bonus for the year of termination.
- CFO John Burns and CDO Dr. Dragan Cicic's change of control severance includes 18 months of COBRA premium reimbursement.
- CFO John Burns and CDO Dr. Dragan Cicic's change of control severance includes immediate vesting of all unvested equity awards.
- The Board of Directors approved these agreements based on the Compensation Committee's recommendation and external consulting review.
Price Impact
More from SLS